Table 1.
Patient characteristics of the overall study cohort of patients with invasive lobular carcinoma (ILC), and in those with early or late ILC recurrence
| Characteristic | Overall (n = 513) | Early recurrence (n = 75) | Late recurrence (n = 54) |
|---|---|---|---|
| Patient characteristics | |||
| Age at diagnosis [mean years (SD)] | 58.8 (11.8) | 59.6 (15.8) | 55.7 (12.5) |
| BMI Category, [n (%)] | |||
| 18.5–25 kg/m2 | 237 (53.1%) | 25 (42.4%) | 16 (39.0%) |
| 25-30 kg/m2 | 133 (29.8%) | 21 (35.6%) | 20 (48.8%) |
| ≥ 30 kg/m2 | 76 (17.0%) | 13 (22.0%) | 5 (12.2%) |
| Systemic therapy [n (%)] | |||
| Any chemotherapy | 198 (39.1%) | 39 (52.7%) | 27 (50.9%) |
| Neoadjuvant chemotherapy | 70 (13.8%) | 17 (23.0%) | 10 (18.9%) |
| Adjuvant endocrine therapy | 395 (78.1%) | 42 (60.0%) | 43 (79.6%) |
| Local therapy [n (%)] | |||
| Lumpectomy | 81 (15.8%) | 19 (25.3%) | 4 (7.41%) |
| Lumpectomy and radiation | 149 (29.1%) | 15 (20.0%) | 18 (33.3%) |
| Mastectomy | 199 (38.9%) | 21 (28.0%) | 20 (37.0%) |
| Mastectomy and radiation | 83 (16.2%) | 20 (26.7%) | 12 (22.2%) |
| Tumor characteristics | |||
| Tumor size [mean cm (SD)] | 3.1 (2.9) | 4.2 (3.9) | 3.3 (2.9) |
| Positive lymph nodes [n (%)] | |||
| 0 nodes | 341 (67.9%) | 33 (44.6%) | 29 (55.8%) |
| 1–3 nodes | 98 (19.5%) | 17 (23.0%) | 13 (25.0%) |
| ≥ 3 nodes | 63 (12.6%) | 24 (32.4%) | 10 (19.2%) |
| Stage [n (%)] | |||
| 1 | 214 (41.7%) | 18 (24.0%) | 20 (37.0%) |
| 2 | 204 (39.8%) | 25 (33.3%) | 21 (38.9%) |
| 3 | 95 (18.5%) | 32 (42.7%) | 13 (24.1%) |
| Grade [n (%)]a | |||
| 1 | 157 (32.3%) | 19 (27.9%) | 13 (29.6%) |
| 2 | 306 (63.0%) | 36 (52.9%) | 29 (65.9%) |
| 3 | 23 (4.7%) | 13 (19.1%) | 2 (4.6%) |
| Ki-67 [mean (SD)]b | 14.2 (14.3) | 21.1 (26.5) | 19.8 (16.7) |
| Lymphovascular invasion [n (%)]c | 41 (8.6%) | 14 (21.2%) | 4 (9.1%) |
| Subtype [n (%)]d | |||
| ER+PR+HER2- | 365 (79.4%) | 40 (61.5%) | 32 (71.1%) |
| ER+PR-HER2- | 56 (12.2%) | 14 (21.5%) | 6 (13.3%) |
| ER-PR-HER2- | 16 (3.48%) | 5 (7.69%) | 3 (6.67%) |
| HER2+ | 23 (5.00%) | 6 (9.23%) | 4 (8.89%) |
| Progesterone receptor [n (%)]e | |||
| ≤ 20% positivity | 151 (34.5%) | 28 (53.9%) | 20 (55.6%) |
| > 20% positivity | 287 (65.5%) | 24 (46.2%) | 16 (44.5%) |
| CTS5 scores [n (%)]f | |||
| Low risk (< 3.13) | 162 (34.4%) | 15 (23.8%) | 10 (23.8%) |
| Intermediate risk (3.13–3.86) | 73 (15.5%) | 6 (9.52%) | 6 (14.3%) |
| High risk (> 3.86) | 236 (50.1%) | 42 (66.7%) | 26 (61.9%) |
aData available for 486 cases
bData Available for 134 cases
cData available for 479 cases
dData available for 460
eData available for 438 cases
fData available for 722 cases
Total overall n = 513, unless otherwise specified. BMI body mass index, LVI lymphovascular invasion, ER estrogen receptor, PR progesterone receptor, HER2, Human Epithelial Growth Factor Receptor-2, CTS5 Clinical Treatment Score 5.